Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
news out!!!
Endonovo Therapeutics Reports Third Quarter 2019 Results
BY GlobeNewswire
— 4:35 PM ET 11/19/2019
Los Angeles, CA, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (ENDV) ("Endonovo" or the "Company"), announced today its financial results for the quarter ended September 30, 2019.
Key Financial Highlights:
Revenues for the three months ended September 30, 2019 increased 153% to $54,039, as compared to $21,306 for the same period last year.
Revenues for the nine months ended September 30, 2019 increased 293% to $161,720, as compared to $41,132 for the same period last year.
Key Business Highlights:
Endonovo is now selling SofPulse®, its noninvasive Electroceutical® therapeutic device, in seven hospitals, eleven surgery centers and fourteen other medical facilities.
Endonovo is in all 50 states covered by either sales representatives and/or master principals.
Endonovo has 113 sales representatives and master principals trained and deployed.
Endonovo is currently in 112 evaluations in hospitals and medical facilities. The Company has 92 hospitals and 20 additional medical centers evaluating SofPulse®.
Endonovo has 8 scientific advisory board members and expanded its management team to include a chief medical officer, a vice president of sales, a vice president of marketing, national sales manager and a strategic advisor to the CEO.
Further developments in studies and trials for additional medical indications including NASH, myocardial infarction, critical limb ischemia, chronic kidney disease, post-concussive syndrome and other studies are postponed until the Company becomes profitable.
Endonovo filed a preliminary information statement on October 31, 2019 and a definitive information statement on November 14, 2019 with respect to a reverse stock split of its common stock at a ratio of between 1 for 100 and 1 for 1,000. The effectiveness of the reverse stock split is contingent upon mailing of the information statement and a twenty-day waiting period, a decision by our sole director as the final ratio of the reverse stock split, filing of a certificate of amendment to our certificate of incorporation and review of the proposal by FINRA. Endonovo can give no information as to the timing and the ratio of the eventual reverse stock split or whether it might actually occur.
Endonovo believes at this time previously disclosed sales projections filed with the Securities and Exchange Commission on June 13, 2019 cannot be relied upon due to delays in approvals by hospitals and evaluation periods within the national rollout plans announced via press release on June 13, 2019.
Alan Collier, CEO of Endonovo Therapeutics (ENDV) stated, “Although our third-quarter operating results and our revenues failed to meet previously announced projections, the efforts throughout the quarter and first nine-months of this year have been extremely positive considering the amount of hospitals we are currently in and the number of hospitals evaluating SofPulse® to date. The national rollout has been successful, however, hospitals testing and evaluation periods have been longer than initially expected. We respect the process, the policies and procedures some hospitals have before accepting a product into their medical facility and as part of their post-operative pain management protocols. As such, we continue to expand our client base and have seen significant traction in building Endonovo into a premier supplier to hospitals nationwide for post-operative pain.”
“We are making bold decisions to accelerate our business and provide us with the ability to take advantage of opportunities in the rapidly changing post-operative pain management business. The opioid epidemic has been a global catastrophe and we remain committed to being at the forefront of replacing opioids in a natural and safe manner,” commented Mr. Collier. “We are targeting areas to drive improved marketing performance and are confident we are pursuing the necessary changes to deliver superior shareholder value.”
About Endonovo Therapeutics (ENDV)
Endonovo Therapeutics, Inc. (ENDV) is a commercial-stage developer of non-invasive wearable Electroceutical® therapeutic devices. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals® therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome and multiple sclerosis. The Company's non-invasive Electroceutical® therapeutic device, SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company's current portfolio of pre-clinical stage Electroceuticals® therapeutic devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The Company's non-invasive, wearable Electroceuticals® therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur. www.endonovo.com
Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.
Investor Relations Contact:
Endonovo Therapeutics, Inc. (ENDV)
Mr. Andrew Barwicki
516-662-9461
Andrew@barwicki.com
www.endonovo.com
Image: Logo.jpg
Source: Endonovo Therapeutics, Inc. (ENDV)
MORE ENDV NEWS
Endonovo Therapeutics Announces Reverse Stock Split
GlobeNewswire - 12:43 PM ET 10/31/2019
Endonovo Therapeutics Appoints Dr. William Li as Strategic Advisor to the CEO
GlobeNewswire - 9:00 AM ET 09/30/2019
Endonovo Partners with Veterans Healthcare Supply Solutions, Appoints Samir Awad, M.D., to Scientific Advisory Board
GlobeNewswire - 9:00 AM ET 09/09/2019
View All
About to take off moving on air
Ryan Schadel
@CRyanSchadel
·
6h
4 week month. Under NDA on the investment sale. Will give info on it as soon as permitted.
$LTNC Correction to my earlier tweet. The revenue cited below does not include gross revenue of $104k the company received from liquidation of an investment that occurred on October 15.
Ryan Schadel
@CRyanSchadel
·
10h
$LTNC system wide revenue for October 2019 $585,715.80. Gross Margin 22.4%. 20 New Customers. Below targets.
If you believe they are scam why don't you report to SEC with evidence that you have?
Thread
Conversation
Ryan Schadel
@CRyanSchadel
·
Oct 11
Once we close out October and review YTD numbers, we will update our plans and targets for our Vision 2025 initiative. Most likely mid November.
$LTNC
Ryan Schadel
@CRyanSchadel
This will follow our annual strategy meeting which planned for the first week of November.
Ryan Schadel
@CRyanSchadel
·
Oct 11
Once we close out October and review YTD numbers, we will update our plans and targets for our Vision 2025 initiative. Most likely mid November.
$LTNC
Ryan Schadel
@CRyanSchadel
·
Oct 7
$LTNC September revenue $462,070. Gross Margins 21.48%.
Ryan Schadel
@CRyanSchadel
·
Oct 7
.
@laborsmart
#Charlotte revenue officially on the books!
Time to increase my stacks of shares?
AS 250,000,000. OS 167,329,067
Did you want to pay it ($12,000) on behalf of the company, if you so believe it has not been paid?
Finger crossed, patience is the only available choice now, I have it.
Time for CEO to wake to their responsibilty see what SEC is doing to protect us:
SEC Proposes Amendments to Enhance Retail Investor Protections
Actions Increase Availability of Issuer Information and Modernize the Rule Governing Quotations for Over-the-Counter Securities
FOR IMMEDIATE RELEASE
2019-189
Washington D.C., Sept. 26, 2019 —
The Securities and Exchange Commission today announced that it has voted to propose amendments to Exchange Act Rule 15c2-11, which sets out certain requirements with which a broker-dealer must comply before it can publish quotations for securities in the over-the-counter (“OTC”) market. The proposed amendments are designed to modernize the Rule, which was last substantively amended in 1991, and to enhance investor protection by requiring that current and publicly available issuer information is accessible to investors. The proposed amendments would provide greater transparency to the investing public by requiring that information about the issuer and the security be current and publicly available before a broker-dealer can begin quoting that security.
Securities that trade on the OTC market are primarily owned by retail investors. Because broker-dealers play an integral role in facilitating investor access to OTC securities and serve an important gatekeeper function under Rule 15c2-11, the Rule requires that a broker-dealer review basic information about an issuer before quoting securities to investors in the OTC market. Certain of the Rule’s exceptions, however, permit broker-dealers to continue to publish quotations when there is no current information about the issuer available to the public or the broker-dealer. The Commission is concerned that, in today’s OTC market, market participants can take advantage of these exceptions to the detriment of retail investors.
Therefore, the Commission is proposing to limit eligibility for some of the exceptions where an issuer’s information becomes unavailable to the public or is no longer current. The proposed amendments would also add new exceptions for broker-dealers quoting certain OTC securities that may be less susceptible to fraud or manipulation.
The proposed amendments contribute to the Commission’s ongoing efforts to better address risks to investors, particularly retail investors. The Commission believes that investors who have access to current and publicly available issuer information are better equipped to make informed decisions about how to allocate their capital.
“Over the past several years, the Commission has brought hundreds of enforcement actions involving tens of millions of dollars in investor harm,” said SEC Chairman Jay Clayton. “When there is little or no current and publicly available information about an issuer, it is difficult for an investor or other market participant to evaluate the issuer and the risks involved in purchasing or selling its securities. Protecting investors by facilitating their access to current and basic information is a core component of our regulatory framework.”
Stephanie Avakian, Co-Director of the Division of Enforcement, said, “This proposal is the result of a multi-year cooperative effort between our Division and the Division of Trading and Markets to prevent the type of microcap fraud that our Enforcement staff sees every day.”
Steven Peikin, Co-Director of the Division of Enforcement, said, “This proposal represents an important proactive step to prevent these types of frauds before investors lose their hard-earned money.”
Brett Redfearn, Director of the Division of Trading and Markets, said, “The proposal focuses on the need for current and publicly available disclosures in over-the-counter securities and at the same time is intended to inhibit a quoted market for OTC securities that may be used as vehicles for fraud. This would result in better protection for investors.”
The public comment period will remain open for 60 days following publication of the proposal in the Federal Register.
* * *
FACT SHEET
Publication or Submission of Quotations Without Specified Information
Proposed Amendments
The Commission proposed amendments to Exchange Act Rule 15c2-11 that are intended to modernize the Rule and better protect retail investors from incidents of fraud and manipulation in over-the-counter (“OTC”) securities. The Rule provides for the publication and submission of quotations by a broker-dealer in a quotation medium for securities that are not listed on a national securities exchange. Prior to submitting or publishing a quotation, a broker-dealer must review certain basic information about an issuer.
The Commission’s proposed amendments would (i) provide greater transparency to investors and other market participants by requiring that information about the issuer and the security be current and publicly available; (ii) limit certain existing exceptions to the Rule to provide greater protections to retail investors; (iii) reduce regulatory burdens on broker-dealers quoting certain OTC securities that may be less susceptible to potential fraud and manipulation; and (iv) streamline the Rule and remove obsolete provisions without undermining the important investor protections of the Rule.
Highlights of Proposed Amendments
Facilitate the availability of current issuer information:
Require the documents and information that the Rule requires broker-dealers to obtain and review to be current and publicly available;
The piggyback exception, which is based on continuous and frequent quotations and allows broker-dealers to publish quotations for a security in reliance on the quotations of a broker-dealer that initially performed the information review required by the Rule, would be amended to require, among other things, that issuer information be current and publicly available; and
Require that certain information be current and publicly available for a broker-dealer to rely on the unsolicited quotation exception to publish quotations by or on behalf of company insiders.
Limit certain exceptions to provide greater protections to investors:
Limit the piggyback exception only to bid and ask quotations that are published at specified prices;
Eliminate the piggyback exception during the first 60 calendar days after the termination of a Commission trading suspension under Section 12(k) of the Exchange Act; and
Eliminate the piggyback exception for securities of “shell companies.”
Reduce burdens for broker-dealers with proposed new exceptions where there is less concern regarding fraud and manipulation:
For securities of well-capitalized issuers whose securities are actively traded;
If the broker-dealer publishing the quotation was named as an underwriter in the security’s registration statement or offering circular;
Where a regulated third party complies with the Rule’s required review and makes known to others the quotation of a broker-dealer relying on the exception; and
In reliance on publicly available determinations by regulated third parties that the requirements of certain exceptions have been met.
The Commission also proposed amendments to streamline the Rule. Additionally, the Commission is seeking public comment on its proposed guidance, as well as a concept release that addresses information repositories and a possible regulatory structure for such entities.
What’s Next?
The public comment period will remain open 60 days following publication of the proposal in the Federal Register.
###
Image Protect Launches Fotofy In-Image Ad Network in $333B Digital Ad Market
BY GlobeNewswire
— 8:02 AM ET 10/01/2019
News out!!!
BioNovelus, Inc. Announces Letter of Intent to Purchase Corvus Consulting, LLC
BY GlobeNewswire
— 9:00 AM ET 09/30/2019
POTOMAC, Md., Sept. 30, 2019 (GLOBE NEWSWIRE) -- BioNovelus, Inc. ( ONOV
Loading...
Loading...
) announces that it has signed a Letter of Intent (LOI) to purchase Corvus Consulting, LLC (“Corvus”).
Corvus, a leading provider of scientific, engineering, technical, operational support, and training services to the federal government and commercial clients, focuses on cyberspace operations, electronic warfare, information operations, intelligence, and joint/electromagnetic spectrum operations. The company’s capabilities include high-level policy development and congressional liaison to requirements analysis, and provides DOTMLPF-p solutions to development assistance and design services for hardware and software systems fulfilling the mission needs of the U.S. Department of Defense and U.S. Intelligence Communities.
Corvus has trailing twelve month revenue in excess of $10 million and is profitable.
“BioNovelus is working closely with the founder of Corvus and anticipates closing the transaction before the end of 2019,” said Mark Fuller, President and CEO of BioNovelus. “We also continue to look at several other acquisition opportunities as we pursue our strategy.”
Forward-Looking Statements:
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters disclosed at www.otcmarkets.com. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements. For instance, the acquisition announced in today’s release may not close despite the best efforts of BioNovelus ( ONOV
Loading...
Loading...
).
Contact:
Mark Fuller, President & CEO
mcfuller79@gmail.com
301-461-1839
Atacama Resources International, Inc. Takes Action to Strengthen Balance Sheet and Position Company for Long Term Success
BY GlobeNewswire
— 9:30 AM ET 09/26/2019
PLANTATION, Fla., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Atacama Resources International, Inc. ( ACRL
Loading...
Loading...
) (“Atacama”), a publicly traded exploration company with over three thousand (3000) acres of mineral claims in Northeastern Ontario, including potential gold, silver, copper, cobalt, and graphite deposits announces that it has reached settlement agreements with convertible debt holders resolving all outstanding indebtedness.
Seven (7) of a total of eight (8) convertible debt holders have been paid in full pursuant to the terms of their respective settlement agreements. The remaining convertible debt holder will be paid in full pursuant to the terms of its settlement agreement no later than November 4, 2019. In addition, Atacama has reached agreements with former officers, management, employees and board members with respect to amounts that were owing and on the company’s books for loans and unpaid salaries and fees.
As noted by Atacama President and Chief Executive Officer, Colin Keith, “The future success of our company depended upon the elimination of this debt. The goal was to create a structure with minimal share consideration, while negotiating - and ultimately obtaining - a number of favorable discounts against contractual terms and premiums.”
"This marks the culmination of an extensive and coordinated effort on the part of the board and management teams, and has given us a strong foundation to pursue our aggressive exploration and asset development strategy for a newly-transformed Atacama. I am excited for the future as I believe in this company and its assets. The impact of the elimination of this debt cannot be overstated, " explained David Berry, Chairman of the Board of Directors.
About Atacama Resources International ( ACRL ) (www.acrlintl.com)
Atacama Resources International ( ACRL
Loading...
Loading...
) is a publicly traded OTC Pink company with significant mining claims in the greater Kirkland Lake area of Northern Ontario. Metals and minerals under potential exploration include gold, silver, copper, graphite and cobalt.
Forward Looking Statements
Certain information set forth in this news announcement may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of Atacama Resources International, Inc. ( ACRL
Loading...
Loading...
). Such forward-looking statements are based on current expectations, estimates and projections about the Company’s industry, management beliefs and certain assumptions made by its management. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. Information concerning factors that could cause the Company's actual results to differ materially from those contained in these forward-looking statements can be found in the Company's periodic reports as filed on the OTC Markets. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise to reflect future events or circumstances or reflect the occurrence of unanticipated events.
For more information please contact:
Crystal Hyde
519-222-3890
crystal@scoutpublicaffairs.com
Image: ATACAMA.jpg
Source: Atacama Resources International, Inc. ( ACRL
Loading...
Loading...
)
MORE ACRL NEWS
Atacama Resources International, Inc. Appoints New Management Team and Technical Advisors
GlobeNewswire - 1:19 PM ET 09/12/2019
Atacama Resources International, Inc. Appoints New Board of Directors
GlobeNewswire - 10:00 AM ET 09/09/2019
news out!
coming storms..
Quite before real storm, .....
Over 34 millions in assets.....
It is sad that all these are allowed. Where is our money?
Time to accumulate more is now I think.
Atacama Resources International, Inc. Appoints New Board of Directors
BY GlobeNewswire
— 10:00 AM ET 09/09/2019
PLANTATION, Fla., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Atacama Resources International, Inc. ( ACRL
Loading...
Loading...
) (“Atacama”), a publicly traded company with significant mining claims in the greater Kirkland Lake area of Northern Ontario, announces the appointment of a new five-member Board of Directors effective September 1, 2019, replacing its existing Board. The new appointees include: David Berry as Acting Chairman, Colin Keith, Stephen Spivak, Waylon Iserhoff, and Dan Finch.
This new dynamic Atacama Board has impressive credentials, extensive business experience and the diversified skill set needed to take the company to the next level. The new Board’s expertise will contribute to positioning Atacama for future growth as the company matures.
“On behalf of the company, I want to express our gratitude to the outgoing Board of Directors for the work they have done to this point and welcome our new Board to the team. I have full confidence that our new Board members will continue to work towards a strong, financially viable future for Atacama, our employees and our shareholders,” said Glenn Grant, President/CEO, Atacama.
“It is a great honour to step into the role of Acting Chairman of the Board at Atacama and I hope to serve the company and its shareholders well by using my experience and leadership skills to improve and grow the business,” said Dave Berry, new Acting Chairman, Atacama.
Atacama Resources International, Inc. ( ACRL ) New Board of Directors:
David Berry – Mr. Berry is widely regarded as the most successful trader in Canadian History. Over his ten (10) year career at ScotiaBank trading its largest proprietary book from 1995 -2005, Mr. Berry increased Scotia’s market share from virtual obscurity to approximately seventy percent (70%). Mr. Berry was also responsible for over forty percent (40%) of the bottom-line P&L for the entire institutional equity department of Scotia Capital during those years, earning in excess of $75 million each year for the bank. Since leaving Scotia, Mr. Berry has been investing his personal capital and largely takes active roles in his investments. Mr. Berry has a mathematics honours degree from Queens University, an MBA from Rotman School of Business, and designations as both a Chartered Accountant and a Certified Financial Analyst.
Colin Keith – An experienced corporate lawyer and business professional, Mr. Keith (B.A., University of Ottawa, and LL.B., University of New Brunswick), services clients throughout Ontario from offices in Timmins and Cochrane in the heart of northeastern Ontario’s gold belt. Mr. Keith began his career in Toronto with a prominent national law firm gaining experience on some of the country’s most complex commercial transactions. Mr. Keith has a highly specialized legal practice which is centered upon a number of key regional industries, including mining.
Stephen Spivak – Mr. Spivak is one of the most successful Gold Options and Futures traders in the history of the Comex Division of the New York Mercantile Exchange and Chicago Mercantile Exchange from 1997-2017. Mr. Spivak has served on the Board of CureDuchenne, a non profit in Orange County, California and was an Advisory Board Member of iBoss, a privately held cyber security company based in Boston, Massachusetts.
Waylon Iserhoff – Mr. Iserhoff has over twenty-five (25) years experience as a finance professional. Most recently, Mr. Iserhoff was the Business and Economic Development Officer for his home community, Taykwa Tagamou Nation, where he supported Chief and Council in the management of its various business interests. Mr. Iserhoff launched his professional career with Deloitte and has held finance roles with two retail organizations and a financial services company. Mr. Iserhoff is a CPA in both Canada and the United States and has an MBA from the Rotman School of Business.
Daniel Finch – Mr. Finch (MBA, Booth School at the University of Chicago) has been president of several NASDAQ and OTC public companies and has spent over thirty (30) years leading high growth companies in a variety of industries.
About Atacama Resources International ( ACRL
Loading...
Loading...
) (www.acrlintl.com)
Atacama Resources International ( ACRL
Loading...
Loading...
) is a publicly traded OTC Pink company with significant mining claims in the greater Kirkland Lake area of Northern Ontario. Metals and minerals under potential exploration include gold, silver, diamonds, graphite and cobalt.
Forward Looking Statements
Certain information set forth in this news announcement may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of Atacama Resources International ( ACRL
Loading...
Loading...
). Such forward-looking statements are based on current expectations, estimates and projections about the Company’s industry, management beliefs and certain assumptions made by its management. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. Information concerning factors that could cause the Company's actual results to differ materially from those contained in these forward-looking statements can be found in the Company's periodic reports as filed on the OTC Markets. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise to reflect future events or circumstances or reflect the occurrence of unanticipated events.
For more information, please contact:
Crystal Hyde
519-222-3890
crystal@scoutpublicaffairs.com
Image: ATACAMA.jpg
Source: Atacama Resources International, Inc. ( ACRL )
MORE ACRL NEWS
ACRL has no more news
Fidelity Investments.Copyright 1998–2019 FMR LLC.
All rights reserved.
I have invested a lot here according to my standard when the company had zero income, now with over $107,000 in six months, i am over joyed that parts started moving in the right direction.
Can you give us a break, when there was no sale you complaint, now sales is moving gradually from nothing to over $107,000 in six mouths, you want bad mouth that success, please.
Only some of the posters here knows what they actually wanted any move there always an attacks, someone just wrote zero volume next week. Hilarious.
Some people are daily con artist.
Some people are disappointed because they can sell their 2s just yet.
The reason for supporting this is no planned R/S. I have been duped so many times with endless reverse split but here the CEO said no reverse split I can live with that.
Hope some Controller Generals here equipped then self with shares..
Over 187 millions in volume so far.
How will the company takes in loses now no dilution, the company get job at certain rate pay employee certain less rate and company make money. i believe we are good with no dilution.
Congrats on your success in real estate. But I strongly believe your successive business was not vertically achieved, there are lot of bumps on the way to success. In the same vein, I believe this CEO is up to something which may not be as quick as we want it. Just tweeted $443.808 GM%22.18 revenue in July alone. I believe because the is the only authentic source of news now others are just conjectures.
can you tell us how many companies were you able to start from the the scratch....to successive level?
your opinion...
What is the meaning of this:
This forecast isn't updated for some reason: missing data or revoked stock.”
Historical index on US Stock Market: C "Should I invest in Solaris Power Cells stock?" "Should I trade "SPCL" stock today?" According to our live Forecast System, Solaris Power Cells, Inc stock is an awesome long-term (1-year) investment*. "SPCL" stock predictions are updated every 5 minutes with latest exchange prices by smart technical market analysis. Q&A about "SPCL" projections.
At Walletinvestor.com we predict future values with technical analysis for wide selection of stocks like Solaris Power Cells, Inc. If you are looking for stocks with good return, Solaris Power Cells, Inc stock can be a profitable 1-year investment option. Solaris Power Cells, Inc real time quote is equal to 79.300 USD at 2019-07-27, but your current investment may be devalued in the future.
Current Price: 79.300 USD
What is going on here, somebody help!